Patrick Hagen
Hematology & Oncology · Maywood, ILNPI 1265725592
Payments from drug & device makers
Across 194 payments — averaging $3879.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$212K
- Takeda Pharmaceuticals U.S.A., Inc.$113K
- Gilead$101K
- Sanofi$87K
- AbbVie$76K
- Janssen Research & Development, LLC$51K
- plus $112K from 11 others
What the payments were for
- Consulting fees$20,63015%
- Speaking & faculty fees$113,29880%
- Travel & lodging$3,3672%
- Food & beverage$3,8693%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 53 | $212,287 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $113,032 |
| Gilead | 4 | $101,212 |
| Sanofi | 46 | $87,472 |
| AbbVie | 4 | $76,164 |
| Janssen Research & Development, LLC | 4 | $50,550 |
| GSK | 3 | $30,495 |
| E.r. Squibb & Sons, L.L.C. | 19 | $28,357 |
| Bristol Myers Squibb | 14 | $16,616 |
| National Marrow Donor Program | 11 | $15,784 |
| Merck | 6 | $12,894 |
| Sanofi-aventis U.S. LLC | 3 | $5,888 |
| Adaptive Biotechnologies Corporation | 13 | $1,670 |
| Akcea Therapeutics, Inc. | 1 | $122 |
| Novartis | 1 | $85 |
| AstraZeneca | 1 | $43 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$752,686 in reported general payments places this provider in the 85th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 317 | $5,895,814 |
| Lenalidomide | 152 | $2,307,408 |
| CalquenceAcalabrutinib Maleate | 66 | $909,547 |
| PomalystPomalidomide | 28 | $612,059 |
| JakafiRuxolitinib Phosphate | 31 | $530,561 |
| BrukinsaZanubrutinib | 24 | $324,991 |
| VenclextaVenetoclax | 31 | $181,285 |
| NinlaroIxazomib Citrate | 14 | $173,042 |
| Imatinib Mesylate | 22 | $43,340 |
| EliquisApixaban | 12 | $14,103 |
| XareltoRivaroxaban | 12 | $6,428 |
| Acyclovir | 96 | $2,145 |
| CholestyramineCholestyramine (With Sugar) | 13 | $1,238 |
| ValacyclovirValacyclovir Hcl | 12 | $725 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 63 | $413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $16,616 | $5,895,814317 claims |
| AstraZenecaCalquence | $43 | $909,54766 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $28,357 | $612,05928 claims |
| AbbVieVenclexta | $76,164 | $181,28531 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $113,032 | $173,04214 claims |
| PfizerEliquis | $212,287 | $14,10312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 580 hematology & oncology providers in Illinois.
Other hematology & oncology in Maywood
- Patrick StiffMaywood$1.2M
- Richard SchilskyBurr Ridge$87.1M
- Edwin PosadasBurr Ridge$70.9M
- Oana DanciuChicago$23.2M
- Shuo MaChicago$20.5M
- Olwen HahnChicago$11.9M
- Christine BestvinaChicago$11.3M
- Russell SzmulewitzChicago$9.8M
- Randy SweisChicago$9.4M
- Hedy KindlerChicago$8.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.